Version 2.77

Description

Delamanid is the first in a new class of anti-mycobacterial agents called bicyclic nitroimidazoles. It is indicated for pulmonary multidrug-resistant tuberculosis (MDR-TB) and is effective against Mycobacterium tuberculosis during replication, dormancy, and intracellular stages. It is primarily metabolized by serum albumin, and does not affect cytochrome P450 metabolic activity. In clinical trials, delamanid was associated with prolonged QTc on EKG that peaks at 8 weeks following the start of therapy and resolves within 4 weeks after stopping therapy, but which did not result in any cardiac events. PMID: 30029909 Source: Regenstrief LOINC

Basic Part Properties

Part Display Name
Delamanid
Part Type
Component (Describes the core component or analyte measured)
Created On
2019-11-02
Construct for LOINC Short Name
Delamanid

LOINC Terminology Service (API) using HL7® FHIR® Get Info

CodeSystem lookup
https://fhir.loinc.org/CodeSystem/$lookup?system=http://loinc.org&code=LP412105-1
ConceptMap translate
https://fhir.loinc.org/ConceptMap/$translate?system=http://loinc.org&code=LP412105-1

Language Variants Get Info

Tag Language Translation
zh-CN Chinese (China) 迪拉马尼
Synonyms: CAS 681492-22-8;OPC-67683
it-IT Italian (Italy) Delamanid
es-ES Spanish (Spain) Delamanid